๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-06-01

Relative Bioavailability Study of HNC364 Injectable Suspension (NCT06798519)

A Relative Bioavailability Study of HNC364 Following Intramuscular Injections vs. AZILECTยฎ (Rasagiline Tablet) Following Oral Administration at the Steady-State in Healthy Adult Subjects

๐Ÿ”ต Active, Not Recruiting Phase1 ๐Ÿ’Š Investigational Drug / Biologic Sponsor: Guangzhou Henovcom Bioscience Co. Ltd.

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

HNC364 is a new pro-drug of rasagiline as a long-acting injection for deep IM deltoid injection, for the treatment of Parkinson"s disease (PD). As a pro-drug of rasagiline, HNC364 will readily and completely convert to rasagiline after the IM administration. This is a non-randomized, open-label, Phase 1 study to evaluate the relative bioavailability of HNC364 injectable suspension relative to AZILECTยฎ (rasagiline tablets), to assess the safety and tolerability of multiple IM dose HNC364 injectable suspension dose administration in healthy adult subjects.

Who can join: Review the eligibility criteria below.

Location: Frontage Clinical Services, Inc. โ€” Secaucus, New Jersey

Age range: 18 Years to 55 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • Frontage Clinical Services, Inc. โ€” Secaucus, New Jersey

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—